Michael Boeckh

Research interests

Publications

• Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation

  Blood · 2021 · https://doi.org/10.1182/blood.2020009396

• Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation

  Immunity · 2020 · https://doi.org/10.1016/j.immuni.2020.06.001

• The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality

  Blood · 2017 · https://doi.org/10.1182/blood-2016-10-748426

• Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy

  Blood · 2017 · https://doi.org/10.1182/blood-2017-07-793760

• Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1706640

• Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study

  The Lancet Haematology · 2016 · https://doi.org/10.1016/s2352-3026(15)00289-6

• Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials: Table 1.

  Clinical Infectious Diseases · 2016 · https://doi.org/10.1093/cid/ciw668

• Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis

  Blood · 2016 · 10.1182/blood-2015-11-679639

• CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia

  Blood · 2013 · https://doi.org/10.1182/blood-2013-02-487074

• Efficacy of a Viral Load-Based, Risk-Adapted, Preemptive Treatment Strategy for Prevention of Cytomegalovirus Disease after Hematopoietic Cell Transplantation

  Transplantation and Cellular Therapy · 2012 · https://doi.org/10.1016/j.bbmt.2012.05.015

• Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients

  Hematology/Oncology Clinics of North America · 2011 · 10.1016/j.hoc.2010.11.011

• Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation

  Blood · 2010 · 10.1182/blood-2010-02-268151

• Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation

  New England Journal of Medicine · 2010 · https://doi.org/10.1056/nejmoa1004383

• How we treat cytomegalovirus in hematopoietic cell transplant recipients

  Blood · 2009 · 10.1182/blood-2008-10-143560

• Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective

  Transplantation and Cellular Therapy · 2009 · https://doi.org/10.1016/j.bbmt.2009.06.019

• Cytomegalovirus Reactivation in Critically Ill Immunocompetent Patients

  JAMA · 2008 · https://doi.org/10.1001/jama.300.4.413

• Toll-like Receptor 4 Polymorphisms and Aspergillosis in Stem-Cell Transplantation

  New England Journal of Medicine · 2008 · https://doi.org/10.1056/nejmoa0802629

• Invasive Aspergillosis following Hematopoietic Cell Transplantation: Outcomes and Prognostic Factors Associated with Mortality

  Clinical Infectious Diseases · 2007 · 10.1086/510592

• Combination Antifungal Therapy for Invasive Aspergillosis

  Clinical Infectious Diseases · 2004 · 10.1086/423380

• Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants

  Blood · 2003 · https://doi.org/10.1182/blood-2003-08-2644

• Cyclophosphamide metabolism is affected by azole antifungals

  Blood · 2003 · https://doi.org/10.1182/blood-2003-07-2512

• Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning

  Blood · 2003 · 10.1182/blood-2003-02-0456

• Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies

  Transplantation and Cellular Therapy · 2003 · 10.1016/s1083-8791(03)00287-8

• High Risk of Death Due to Bacterial and Fungal Infection among Cytomegalovirus (CMV)–Seronegative Recipients of Stem Cell Transplants from Seropositive Donors: Evidence for Indirect Effects of Primary CMV Infection

  The Journal of Infectious Diseases · 2002 · 10.1086/338624

• Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors

  Blood · 2002 · https://doi.org/10.1182/blood-2002-05-1496

• Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity

  Blood · 2002 · https://doi.org/10.1182/blood-2002-03-0993

• Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants

  The Lancet · 2000 · 10.1016/s0140-6736(00)02607-6

• Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial

  Blood · 2000 · 10.1182/blood.v96.6.2055

• Increased Incidence of Cytomegalovirus Disease After Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation

  Blood · 1999 · https://doi.org/10.1182/blood.v94.12.4029

• Quantitation of Cytomegalovirus: Methodologic Aspects and Clinical Applications

  Clinical Microbiology Reviews · 1998 · 10.1128/cmr.11.3.533

• Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study

  Blood · 1996 · 10.1182/blood.v88.10.4063.bloodjournal88104063

Current projects

No projects listed.